United Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . United Therapeutics
UTHR Stock  USD 378.13  1.13  0.30%   
United Therapeutics financial statements provide useful quarterly and yearly information to potential United Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on United Therapeutics financial statements helps investors assess United Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting United Therapeutics' valuation are summarized below:
Gross Profit
1.8 B
Profit Margin
0.4031
Market Capitalization
16.9 B
Enterprise Value Revenue
5.0631
Revenue
2.8 B
There are over one hundred nineteen available fundamental trend indicators for United Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check United Therapeutics' current fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 11/29/2024, Market Cap is likely to grow to about 12 B. Also, Enterprise Value is likely to grow to about 11.8 B

United Therapeutics Total Revenue

2.44 Billion

Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0114 or PTB Ratio of 1.63. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
  
Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

United Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.5 B7.2 B3.5 B
Slightly volatile
Short and Long Term Debt Total735 M700 M421.5 M
Slightly volatile
Other Current Liabilities418.7 M398.8 M217.1 M
Slightly volatile
Total Current Liabilities844.6 M804.4 M410.8 M
Slightly volatile
Total Stockholder Equity6.3 B6 B2.7 B
Slightly volatile
Property Plant And Equipment Net1.1 B1 B616.7 M
Slightly volatile
Accounts Payable10.2 M5.6 M10.5 M
Slightly volatile
Cash1.3 B1.2 B669.2 M
Slightly volatile
Non Current Assets Total3.8 B3.6 B1.8 B
Slightly volatile
Non Currrent Assets Other91.5 M151.8 M119.7 M
Slightly volatile
Cash And Short Term Investments3.1 B3 B1.8 B
Slightly volatile
Net Receivables292.8 M278.9 M178.3 M
Slightly volatile
Common Stock Shares Outstanding50.7 M49.7 M47.2 M
Pretty Stable
Liabilities And Stockholders Equity7.5 B7.2 B3.5 B
Slightly volatile
Non Current Liabilities Total269.4 M377.8 M390 M
Slightly volatile
Other Current Assets174.5 M166.2 M86.4 M
Slightly volatile
Total Liabilities1.2 B1.2 B811.9 M
Slightly volatile
Total Current Assets3.7 B3.6 B1.7 B
Slightly volatile
Good Will35.4 M33.7 M19.3 M
Slightly volatile
Common Stock Total Equity531.1 K805 K643.5 K
Slightly volatile
Short Term Investments1.9 B1.8 B723 M
Slightly volatile
Property Plant And Equipment Gross1.5 B1.5 B723.7 M
Slightly volatile
Short Term Debt483 M460 M274.8 M
Slightly volatile
Intangible Assets84.5 M80.5 M47.8 M
Slightly volatile
Common Stock540.6 K805 K644.1 K
Slightly volatile
Other Liabilities60.5 M88.3 M87.5 M
Very volatile
Other Assets284.7 M475.5 M379.8 M
Slightly volatile
Inventory55.9 M111.8 M75.6 M
Slightly volatile
Property Plant Equipment1 B990.7 M609.5 M
Slightly volatile
Current Deferred Revenue395.8 M377 M284.3 M
Pretty Stable
Preferred Stock Total Equity17.5 M22.1 M18.5 M
Pretty Stable
Net Tangible Assets5.7 B5.5 B2.6 B
Slightly volatile
Warrants20 M22.1 M20.1 M
Very volatile
Long Term Debt Total469.1 M920 M398.7 M
Slightly volatile
Capital Surpluse1.9 B2.7 B1.8 B
Slightly volatile
Long Term Investments2 B1.9 B752 M
Slightly volatile
Non Current Liabilities Other98.1 M77.8 M93.6 M
Very volatile
Deferred Long Term Asset Charges133.2 M86.1 M143.5 M
Slightly volatile
Short and Long Term Debt483 M460 M252 M
Slightly volatile
Net Invested Capital4.8 B6.7 B3.4 B
Slightly volatile
Net Working Capital2.1 B2.7 B1.5 B
Slightly volatile
Capital Stock598.5 K630 K12.2 M
Slightly volatile

United Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue2.4 B2.3 B1.5 B
Slightly volatile
Gross Profit2.2 B2.1 B1.3 B
Slightly volatile
Other Operating Expenses1.2 B1.1 B819.2 M
Slightly volatile
Research Development239.6 M408 M331.5 M
Slightly volatile
Total Operating Expenses469.6 M885.1 M659.7 M
Slightly volatile
Selling General Administrative207.3 M395.3 M279 M
Slightly volatile
Cost Of Revenue270.4 M257.5 M129 M
Slightly volatile
Selling And Marketing Expenses77.7 M81.8 M295 M
Slightly volatile
Discontinued Operations5.6 K6.3 K6.9 K
Slightly volatile
Interest Income170.8 M162.7 M35.9 M
Slightly volatile
Reconciled Depreciation49.8 M53.2 M38.9 M
Slightly volatile

United Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1 B961.2 M588.5 M
Slightly volatile
Capital Expenditures241.9 M230.4 M97.8 M
Slightly volatile
End Period Cash Flow1.3 B1.2 B670.6 M
Slightly volatile
Issuance Of Capital Stock3.1 M3.5 M3.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.24.421471.6302
Slightly volatile
Dividend Yield0.01140.01290.014
Slightly volatile
PTB Ratio1.631.71953.0139
Slightly volatile
Days Sales Outstanding84.5243.737372.3313
Slightly volatile
Book Value Per Share13412858.4088
Slightly volatile
Average Payables5.4 M4.8 M6.3 M
Slightly volatile
PB Ratio1.631.71953.0139
Slightly volatile
EV To Sales3.994.203367.1499
Slightly volatile
Inventory Turnover1.192.30321.5747
Pretty Stable
Days Of Inventory On Hand151158278
Pretty Stable
Payables Turnover48.2845.982119.441
Slightly volatile
Sales General And Administrative To Revenue0.160.16981.0215
Slightly volatile
Average Inventory2.4 M4 M4.1 M
Very volatile
Research And Ddevelopement To Revenue0.170.17535.344
Slightly volatile
Capex To Revenue0.0940.0990.443
Slightly volatile
Cash Per Share67.1863.976531.6387
Slightly volatile
Payout Ratio1.191.341.4606
Slightly volatile
Days Payables Outstanding7.547.937973.1442
Slightly volatile
Income Quality1.060.99311.2164
Very volatile
Intangibles To Total Assets0.01510.01590.0205
Very volatile
Current Ratio7.294.41455.0489
Slightly volatile
Tangible Book Value Per Share13212556.9349
Slightly volatile
Receivables Turnover5.558.34537.6116
Slightly volatile
Graham Number258246115
Slightly volatile
Shareholders Equity Per Share13412858.4088
Slightly volatile
Debt To Equity0.170.1170.1547
Pretty Stable
Capex Per Share5.174.92312.121
Slightly volatile
Revenue Per Share52.2249.732931.5552
Slightly volatile
Interest Debt Per Share17.0416.22449.3034
Slightly volatile
Debt To Assets0.10.09770.1095
Pretty Stable
Operating Cycle192202347
Slightly volatile
Price Book Value Ratio1.631.71953.0139
Slightly volatile
Days Of Payables Outstanding7.547.937973.1442
Slightly volatile
Dividend Payout Ratio1.191.341.4606
Slightly volatile
Ebt Per Ebit1.191.07541.0344
Pretty Stable
Effective Tax Rate0.240.22720.2806
Very volatile
Company Equity Multiplier1.11.19751.342
Slightly volatile
Long Term Debt To Capitalization0.0880.04770.1142
Pretty Stable
Total Debt To Capitalization0.110.10470.1272
Pretty Stable
Debt Equity Ratio0.170.1170.1547
Pretty Stable
Quick Ratio6.964.27554.8312
Slightly volatile
Net Income Per E B T0.920.77280.7304
Pretty Stable
Cash Ratio1.431.50141.8746
Pretty Stable
Days Of Inventory Outstanding151158278
Pretty Stable
Days Of Sales Outstanding84.5243.737372.3313
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.080.76440.9057
Very volatile
Price To Book Ratio1.631.71953.0139
Slightly volatile
Fixed Asset Turnover1.892.22642.2297
Pretty Stable
Debt Ratio0.10.09770.1095
Pretty Stable
Price Sales Ratio4.24.421471.6302
Slightly volatile
Asset Turnover0.290.32480.4444
Pretty Stable
Price Fair Value1.631.71953.0139
Slightly volatile

United Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12 B11.4 B9.1 B
Slightly volatile
Enterprise Value11.8 B11.2 B8.6 B
Slightly volatile

United Fundamental Market Drivers

Forward Price Earnings13.8504
Cash And Short Term Investments3 B

United Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About United Therapeutics Financial Statements

United Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in United Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on United Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue377 M395.8 M
Total Revenue2.3 B2.4 B
Cost Of Revenue257.5 M270.4 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.17  0.16 
Research And Ddevelopement To Revenue 0.18  0.17 
Capex To Revenue 0.10  0.09 
Revenue Per Share 49.73  52.22 
Ebit Per Revenue 0.51  0.53 

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

  0.64EWTX Edgewise TherapeuticsPairCorr
  0.65BHC Bausch Health CompaniesPairCorr

Moving against United Stock

  0.7HLN Haleon plcPairCorr
  0.67JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.65MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.65ZTS Zoetis IncPairCorr
  0.57LLY Eli Lilly Sell-off TrendPairCorr
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY